Cancer researchers at the University of Bath measured systematically how effective molecules to inhibit activity of a protein associated with prostate and other cancers. The molecules could eventually be turned into new anticancer drugs.
Study group of the compartments of Pharmacy and Pharmacology, Chemistry and studying protein called α-metilatsil-CoA racemase (AMACR), as a potential target for cancer therapy. AMACR protein levels and activity are increased in ~ 10 times in all prostate cancers. The decrease in these levels with the use of genetic methods makes cancer cells less aggressive, and their behavior is more like normal cells.
Until relatively recently, the discovery of molecules that could migrate and inhibit AMACR, was difficult because it was difficult to accurately measure the levels of activity of the protein. However, after the development of a simple test for the color change, which can do just that, of Bath University team was able to start an analysis of the structure of promising molecules affects the AMACR activity.
The team systematically changed the molecules to determine which parts are important for the effectiveness of anti-AMACR.
Information from the tests will help the team move on to more promising anticancer drugs. Their next steps are to use the information to develop a rational, even more potent molecules for testing against AMACR.
The study is published in "Bioorganic Chemistry" magazine.
Lead author Dr. Matthew Lloyd said: "This is a small but important step in the development of new treatments for cancer of the prostate based on the inhibition of AMACR This is important because it provides a basis for forecasting and evaluating the effectiveness of the drug Development of.. new treatments for cancer of the prostate and other cancers in which AMACR levels increase.
"The test we developed in Bath, makes this work possible and will now allow us to continue to work on new anti-cancer drugs."
The study was funded by the Prostate Cancer UK with the support of Movember Foundation as part of their initiative to develop new treatments for prostate cancer.
Dr Matthew Hobbs, deputy director of research in the field of prostate cancer the UK, said: "More than 11,000 people die each year from prostate cancer in the UK, making it the third biggest cancer killer These men the cancer cells of the. prostate grow and develop and eventually become resistant to treatment, which is currently available to combat this disease. However, important research like this that seek to find new ways to treat prostate cancer , Can stop this trend.
"Thanks to the funds received from the UK prostate cancer advocates and Moveva Foundation, this research possible."
In the UK, prostate cancer is the most common disease that is specific for men, with 47,151 new diagnosis, registered in 2015, and 11,287 deaths in 2014. While 84% of men will survive for at least 10 years with the disease, new treatments are urgently needed, especially for those men diagnosed with a more advanced stage.